Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalkKatrin D. Mayer-Barber, Alan Sher|Nature|2014Cited by 776
Successful T cell priming in B cell-deficient mice.M. Epstein, Polly Matzinger, Alan Sher et al.|The Journal of Experimental Medicine|1995Cited by 275
Effector Cells of Both Nonhemopoietic and Hemopoietic Origin Are Required for Interferon (IFN)-γ– and Tumor Necrosis Factor (TNF)-α–dependent Host Resistance to the Intracellular Pathogen, <i>Toxoplasma gondii </i>George Yap, Alan Sher|The Journal of Experimental Medicine|1999Cited by 244
Pharmacological Inhibition of Host Heme Oxygenase-1 Suppresses Mycobacterium tuberculosis Infection <i>In Vivo</i> by a Mechanism Dependent on T LymphocytesDiego L. Costa, Alan Sher|mBio|2016Cited by 53
Heme oxygenase-1 inhibition promotes IFNγ- and NOS2-mediated control of Mycobacterium tuberculosis infectionDiego L. Costa, Alan Sher|Mucosal Immunology|2020Cited by 33